Dobutamine

Summary

Dobutamine (CHEMBL926) is an approved small-molecule cardiotonic drug (ATC C01CA07) targeting ADRB1; indicated across 7 conditions including cardiovascular disorder and heart failure.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01CA07
• Targets: 1 (ADRB1)
• Indications: 7 conditions
• Clinical trials: 55
• Chemistry: 301.4 Da · C18H23NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL926
Name	Dobutamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	36811
ChEBI	CHEBI:4670
ATC	C01CA07
Molecular formula	C18H23NO3
Molecular weight	301.4
InChIKey	JRWZLRBJNMZMFE-UHFFFAOYSA-N

SMILES: CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O

IUPAC name: 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol

ChEBI definition: A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A β1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.

Pharmacological roles (ChEBI): cardiotonic drug, sympathomimetic agent, β-adrenergic agonist.

Also known as: COMPOUND 81929, COMPOUND-81929, Dl-dobutamine, Dobutamina, Dobutamine, Racemic dobutamine, SID26751752, SID90341592, dobutamine, SID104171143, SID50104446, DOBUTAMINE

Parent form; salt/anhydrous children: CHEMBL1200418, CHEMBL4297079

Patent coverage: 4,481 distinct patent families (17,095 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 17,091 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRB1	β1-adrenoceptor	Partial agonist	6.8	0%	P08588

Broader ChEMBL bioactivity targets: 46 (assay-derived). Sample: Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Tyrosine-protein kinase Fyn, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Epidermal growth factor receptor, Carbonic anhydrase 2, D(1A) dopamine receptor.

Bioactivity

ChEMBL activities: 56 potent at pChembl ≥ 5 of 65 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1A	8.27	AC50	5.4	nM	CHEMBL_ACT_25229731
P43140	7.35	Ki	45	nM	CHEMBL_ACT_7698724
ADRA1D	7.25	Ki	56	nM	CHEMBL_ACT_7698728
ADRA1A	7.15	AC50	70.4	nM	CHEMBL_ACT_25138401
P43140	6.96	IC50	110	nM	CHEMBL_ACT_7698723
ADRA1D	6.94	IC50	114	nM	CHEMBL_ACT_7698727
SLC6A3	6.91	Ki	123	nM	CHEMBL_ACT_7700820
SLC6A3	6.81	IC50	155	nM	CHEMBL_ACT_7700819
P15823	6.73	Ki	186	nM	CHEMBL_ACT_7698726
ADRA1A	6.59	AC50	255.1	nM	CHEMBL_ACT_25137875
P15823	6.47	IC50	336	nM	CHEMBL_ACT_7698725
SLC6A2	6.42	IC50	383	nM	CHEMBL_ACT_7700755
SLC6A2	6.42	Ki	380	nM	CHEMBL_ACT_7700756
Q99N23	6.41	Ki	390	nM	CHEMBL_ACT_3426932
CA2	6.32	Ki	480	nM	CHEMBL_ACT_3426855
P12530	6.22	IC50	599	nM	CHEMBL_ACT_7700863
DRD3	6.14	AC50	728	nM	CHEMBL_ACT_25193427
CA5A	6.14	Ki	730	nM	CHEMBL_ACT_3426876
ADRA2C	6.1	AC50	798.1	nM	CHEMBL_ACT_25147775
SLC6A3	6.05	AC50	897.2	nM	CHEMBL_ACT_25123852
CA5B	6.05	Ki	890	nM	CHEMBL_ACT_3426883
SLC6A4	6	Ki	1006	nM	CHEMBL_ACT_7702975
ADRB2	5.98	Ki	1043	nM	CHEMBL_ACT_7700752
SIGMAR1	5.98	Ki	1058	nM	CHEMBL_ACT_7702977
ADRB1	5.95	Ki	1123	nM	CHEMBL_ACT_7700750
ADRA2B	5.87	Ki	1354	nM	CHEMBL_ACT_7698732
ADRB2	5.82	IC50	1517	nM	CHEMBL_ACT_7700751
OPRM1	5.77	AC50	1700	nM	CHEMBL_ACT_25157384
DRD3	5.77	Ki	1693	nM	CHEMBL_ACT_7700816
SLC6A2	5.76	AC50	1725	nM	CHEMBL_ACT_25144902

Target pathways

Aggregated over 1 target gene(s): ADRB1.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	ADRB1
Signaling by GPCR	1	ADRB1
Class A/1 (Rhodopsin-like receptors)	1	ADRB1
Amine ligand-binding receptors	1	ADRB1
GPCR downstream signalling	1	ADRB1
Adrenoceptors	1	ADRB1
G alpha (s) signalling events	1	ADRB1
GPCR ligand binding	1	ADRB1

Dominant GO biological processes

GO term	Targets
positive regulation of heart rate by epinephrine-norepinephrine	1
positive regulation of the force of heart contraction by epinephrine-norepinephrine	1
diet induced thermogenesis	1
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
response to cold	1
positive regulation of cardiac muscle cell apoptotic process	1
heat generation	1
negative regulation of multicellular organism growth	1
fear response	1
positive regulation of MAPK cascade	1
regulation of circadian sleep/wake cycle, sleep	1
brown fat cell differentiation	1
adenylate cyclase-activating adrenergic receptor signaling pathway	1
positive regulation of cold-induced thermogenesis	1

Indications & clinical

Indications

7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
heart failure	3	MONDO:0005252	EFO:0003144
toxic shock syndrome	2	MONDO:0001881	EFO:0006834
acute lung injury	2	MONDO:0015796	EFO:0004610
brain injury	2	MONDO:0043510	MONDO:0043510
burn	0	MONDO:0043519	EFO:0009516

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 55.

Phase distribution

Phase	Trials
Not specified	21
PHASE4	12
PHASE2	8
PHASE3	4
PHASE1/PHASE2	4
EARLY_PHASE1	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05267886	PHASE4	RECRUITING	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
NCT00484133	PHASE4	UNKNOWN	Microcirculation Guided Therapy Versus Standard Treatment of Severe Sepsis
NCT00549419	PHASE4	COMPLETED	Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Abdominal Surgery
NCT01375335	PHASE4	SUSPENDED	The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement
NCT01418118	PHASE4	COMPLETED	Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
NCT01427686	PHASE4	UNKNOWN	Dopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates
NCT01930734	PHASE4	UNKNOWN	Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients
NCT01969071	PHASE4	COMPLETED	The Effects of Levosimendan During Mitral Valve Surgery
NCT02012946	PHASE4	UNKNOWN	Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery
NCT02767024	PHASE4	WITHDRAWN	Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure
NCT03207165	PHASE4	COMPLETED	Milrinone Versus Dobutamine in Critically Ill Patients
NCT03846765	PHASE4	COMPLETED	Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS).
NCT00001891	PHASE3	COMPLETED	Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle
NCT00093301	PHASE2/PHASE3	UNKNOWN	Levosimendan Versus Dobutamine in Shock Patients
NCT00148278	PHASE2/PHASE3	COMPLETED	Norepinephrine Plus Dobutamine Versus Epinephrine Alone for the Management of Septic Shock
NCT00348504	PHASE3	COMPLETED	Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.
NCT02133105	PHASE3	COMPLETED	Levosimendan Versus Dobutamine for Renal Function in Heart Failure
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05350592	PHASE2	ACTIVE_NOT_RECRUITING	Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
NCT06878742	PHASE1/PHASE2	RECRUITING	Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants
NCT07406477	PHASE2	NOT_YET_RECRUITING	The PROTECT-HIE Pilot Trial
NCT00281255	PHASE1/PHASE2	WITHDRAWN	Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy
NCT00624650	PHASE2	COMPLETED	Hemodynamics and Extravascular Lung Water in Acute Lung Injury
NCT00800306	PHASE2	COMPLETED	Effects of Levosimendan on Microcirculation in Septic Shock
NCT01605279	PHASE2	COMPLETED	Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns
NCT02019810	PHASE2	UNKNOWN	Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury
NCT02644057	PHASE2	WITHDRAWN	Dobutamaine Versus Milrinone in Cardiorenal Syndrome
NCT03311178	PHASE1/PHASE2	TERMINATED	Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period
NCT04020172	PHASE1/PHASE2	COMPLETED	Improving Tissue Oxygenation in Breast Reconstruction Surgery
NCT05953142	PHASE2	UNKNOWN	Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.
NCT00763035	EARLY_PHASE1	TERMINATED	Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
NCT04249258	EARLY_PHASE1	COMPLETED	Dobutamine on the Cardiac Conduction System
NCT05241912	EARLY_PHASE1	UNKNOWN	Supernormal Oxygen Delivery for Patients With Severe Burns
NCT06210217	EARLY_PHASE1	UNKNOWN	Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum
NCT05944146	Not specified	RECRUITING	Consistency of Carotid Doppler Blood Flow and Thermodilution Technique
NCT00074724	Not specified	COMPLETED	Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization
NCT00250315	Not specified	COMPLETED	DOCICAR: Cardiac Dysfunction in Cirrhosis
NCT00557934	Not specified	COMPLETED	Right Ventricular Contractility Reserve Following Repair of Tetralogy of Fallot
NCT01271153	Not specified	COMPLETED	Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients
NCT01354613	Not specified	COMPLETED	Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

179 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	ADRB1
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRB1
ACEBUTOLOL	ChEMBL	Phase 4 (approved)	ADRB1
ALBUTEROL	ChEMBL	Phase 4 (approved)	ADRB1
AMIODARONE	ChEMBL	Phase 4 (approved)	ADRB1
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB1
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB1
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB1
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRB1
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRB1
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRB1
BENFLUOREX	ChEMBL	Phase 4 (approved)	ADRB1
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRB1
BENZBROMARONE	ChEMBL	Phase 4 (approved)	ADRB1
BEPRIDIL	ChEMBL	Phase 4 (approved)	ADRB1
BETAXOLOL	ChEMBL	Phase 4 (approved)	ADRB1
BISOPROLOL	ChEMBL	Phase 4 (approved)	ADRB1
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB1
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRB1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	ADRB1
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRB1
CARTEOLOL	ChEMBL	Phase 4 (approved)	ADRB1
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRB1
CELIPROLOL	ChEMBL	Phase 4 (approved)	ADRB1
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRB1
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	ADRB1
CINACALCET	ChEMBL	Phase 4 (approved)	ADRB1
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRB1
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRB1
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRB1
CODEINE	ChEMBL	Phase 4 (approved)	ADRB1
DARIFENACIN	ChEMBL	Phase 4 (approved)	ADRB1
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	ADRB1
DECITABINE	ChEMBL	Phase 4 (approved)	ADRB1
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRB1
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRB1
DULOXETINE	ChEMBL	Phase 4 (approved)	ADRB1
EBASTINE	ChEMBL	Phase 4 (approved)	ADRB1
ECONAZOLE	ChEMBL	Phase 4 (approved)	ADRB1
EFAVIRENZ	ChEMBL	Phase 4 (approved)	ADRB1
EPALRESTAT	ChEMBL	Phase 4 (approved)	ADRB1
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB1
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRB1
ESMOLOL	ChEMBL	Phase 4 (approved)	ADRB1
FENOTEROL	ChEMBL	Phase 4 (approved)	ADRB1
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	ADRB1
FORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB1
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRB1
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	ADRB1
ISOCONAZOLE	ChEMBL	Phase 4 (approved)	ADRB1
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB1
LABETALOL	ChEMBL	Phase 4 (approved)	ADRB1
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	ADRB1
LEVOBUNOLOL	ChEMBL	Phase 4 (approved)	ADRB1
LORCASERIN	ChEMBL	Phase 4 (approved)	ADRB1
METARAMINOL	ChEMBL	Phase 4 (approved)	ADRB1
METHYLERGONOVINE	ChEMBL	Phase 4 (approved)	ADRB1
METOPROLOL	ChEMBL	Phase 4 (approved)	ADRB1
MICONAZOLE	ChEMBL	Phase 4 (approved)	ADRB1
MONTELUKAST	ChEMBL	Phase 4 (approved)	ADRB1